248 related articles for article (PubMed ID: 15256245)
1. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.
Thomas JM; Clark MA
Eur J Surg Oncol; 2004 Aug; 30(6):686-91. PubMed ID: 15256245
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
[TBL] [Abstract][Full Text] [Related]
3. Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?
Cerovac S; Mashhadi SA; Williams AM; Allan RA; Stanley PR; Powell BW
J Plast Reconstr Aesthet Surg; 2006; 59(5):487-93. PubMed ID: 16631558
[TBL] [Abstract][Full Text] [Related]
4. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.
Pawlik TM; Ross MI; Shaw HM; Thompson JF; Gershenwald JE
Eur J Surg Oncol; 2005 Apr; 31(3):323-4. PubMed ID: 15780572
[No Abstract] [Full Text] [Related]
5. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma.
Molenkamp BG; Statius Muller MG; Vuylsteke RJ; van der Sijp JR; Meijier S; van Leeuwen PA
Eur J Surg Oncol; 2005 Mar; 31(2):211-2. PubMed ID: 15698742
[No Abstract] [Full Text] [Related]
6. Melanoma of the ear: prognostic factors and surgical strategies.
Jahn V; Breuninger H; Garbe C; Moehrle M
Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma.
Kang JC; Wanek LA; Essner R; Faries MB; Foshag LJ; Morton DL
J Clin Oncol; 2005 Jul; 23(21):4764-70. PubMed ID: 16034052
[TBL] [Abstract][Full Text] [Related]
8. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
9. Patterns of drainage and recurrence following sentinel lymph node biopsy for cutaneous melanoma of the head and neck.
Fincher TR; O'Brien JC; McCarty TM; Fisher TL; Preskitt JT; Lieberman ZH; Stephens JF; Kuhn JA
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):844-8. PubMed ID: 15262761
[TBL] [Abstract][Full Text] [Related]
10. The chances of a patient with melanoma developing in transit disease are doubled by undergoing sentinel lymph node biopsy (SLNB).
Russell-Jones R; Powell AM; Acland K; Calonje E; O'Doherty M; Healy C
Eur J Surg Oncol; 2005 Mar; 31(2):210-1. PubMed ID: 15698741
[No Abstract] [Full Text] [Related]
11. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
12. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma.
van Poll D; Thompson JF; Colman MH; McKinnon JG; Saw RP; Stretch JR; Scolyer RA; Uren RF
Ann Surg Oncol; 2005 Aug; 12(8):597-608. PubMed ID: 16021534
[TBL] [Abstract][Full Text] [Related]
13. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors for in-transit metastasis in patients with cutaneous melanoma].
Clemente-Ruiz de Almiron A; Serrano-Ortega S
Actas Dermosifiliogr; 2012 Apr; 103(3):207-13. PubMed ID: 21899829
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
[TBL] [Abstract][Full Text] [Related]
16. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
[TBL] [Abstract][Full Text] [Related]
17. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity.
Leong WL; Ghazarian DM; McCready DR
J Surg Oncol; 2003 Mar; 82(3):143-6. PubMed ID: 12619055
[TBL] [Abstract][Full Text] [Related]
18. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.
Guggenheim MM; Hug U; Jung FJ; Rousson V; Aust MC; Calcagni M; Künzi W; Giovanoli P
Ann Surg; 2008 Apr; 247(4):687-93. PubMed ID: 18362633
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
20. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
